Objectives: This study sought to evaluate the feasibility and safety of autologous bone
marrow–derived and cardiogenically oriented mesenchymal stem cell therapy and to probe …

Background—SCIPIO is a first-in-human, phase 1, randomized, open-label trial of
autologous c-kit+ cardiac stem cells (CSCs) in patients with heart failure of ischemic etiology …

Background—Cardiac cell therapy for older patients who experience a myocardial infarction
may require highly regenerative cells from young, healthy (allogeneic) donors. Bone marrow …

Stem cell-based therapy is emerging as a promising strategy to treat end-stage heart failure,
a leading cause of morbidity and mortality. Stem cells can be isolated from a variety of …

The restoration of functional myocardium following heart failure still remains a formidable
challenge among researchers. Irreversible damage caused by myocardial infarction is …

After a myocardial infarction, heart tissue becomes irreversibly damaged, leading to scar
formation and inevitably ischemic heart failure. Of the many available interventions after a …

Acute ischemic injury and chronic cardiomyopathies can cause irreversible loss of cardiac
tissue leading to heart failure. Cellular therapy offers a new paradigm for treatment of heart …

Heart failure is a major cause of mortality worldwide with a steady increase in prevalence.
There is currently no available cure beyond orthotopic heart transplantation, which for a …

Background: Both bone marrow–derived mesenchymal stem cells (MSCs) and c-kit+ cardiac
stem cells (CSCs) improve left ventricular remodeling in porcine models and clinical trials …

'd like to give you an overall view of what is going on in stem cell therapy for cardiovascular
disease. There are 2 major types of cells to consider (Fig. 1). One is skeletal myoblasts …